Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

Vaccine 2007 Conference was organized

under the guidance of the Global HIV Vaccine Enterprise, an alliance of

independent global organizations dedicated to accelerating preventative

AIDS vaccine development. The conference reported the AIDS epidemic

continuing as a global threat with the disease increasing in every

region of the world, especially East and Central Asia and Eastern

Europe where AIDS incidence was 21% higher in 2006 than in 2004.

Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the

AIDS Vaccine 2007 Conference included:

* GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate

anti-HIV/AIDS immune responses) at both low (1/10th) dose and full

doses.

* GeoVax vaccines were well tolerated with no or mild local and

systemic reactions in the majority of trial participants.

* 80% of both the low and full dose trial participants responded to

the vaccine which stimulated highly desirable anti-HIV T-cell

(white blood cell) and antibody responses.

* More volunteers had antibody responses to the full dose than to the

1/10th dose vaccine, whereas response rates for T cells were

similar for the 1/10th and full dose.

* 2nd MVA vaccination positively increased the number of CD8 T cell

responders and antibody responders.

* Excellent results led to authorization to start two new trials with

GeoVax HIV/AIDS vaccines which began in June 2007.

-- On September 21, 2007, Merck & Co., Inc. announced their candidate AIDS

vaccine failed to provide protection in a human study designed to test

for efficacy. In this Merck trial involving high risk volunteers, an

equal number of people received either placebo or AIDS vaccine. The

independent Data Safety Monitori
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... 2014 As DePuy Pinnacle hip lawsuits ... courts, Bernstein Liebhard LLP notes the publication of a ... the failure of metal-on-metal hip replacements. The research, which ... of Bone & Joint Surgery, looked at 597 ... prostheses at least twelve months earlier. The blood metal ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Arab Emirates (PRWEB) July 12, 2014 ... Los Angeles basketball legend is heading to the UAE. ... and six-time champion will be in the UAE from ... Fitness Weekend in support of diabetes awareness. The event ... award-winning entertainment marketing and event management company based in ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... 2011) -Texas Children,s Hospital in Houston announces that ... earned a National Science Foundation Early Career Development (CAREER) ... congenital heart disease, heart defects, and the development of ... amniotic fluid. The award comes with new funding of ...
... brain function variations between the left and right sides ... weight of the placenta. The finding could shed new ... later life. The research, conducted at the University ... Epidemiology Unit at Southampton General Hospital, reveals that children ...
... Spanish . Between 5 % and 10 % of ... father or mother a mutation in a gene that is susceptible to ... of the genes to be monitored. It is estimated that 30 % ... these two genes (which suggests, at the same time, that there are ...
... the University of the Basque Country (UPV/EHU) has carried ... between the sexes and generations in terms of forgiveness. ... while women are better at forgiving than men. ... it shows us what reasons people have for forgiving ...
... both type 1 diabetes and CKD have an increased ... with type 1 diabetes and overt nephropathy develop End-Stage ... The competing risks of death and ESRD may confound ... Now, the researchers at the University of Helsinki, University ...
... Reporter , THURSDAY, Feb. 17 (HealthDay News) -- Cyclists ... street traffic have fewer accidents compared to bikers pedalling ... found that there is a 28 percent lower injury ... in parallel and comparable roads," noted study lead author ...
Cached Medicine News:Health News:Tissue engineering methods earn funding to heal little hearts 2Health News:Brain function linked to birth size in groundbreaking new study 2Health News:Ph.D. thesis on 2 genes involved in hereditary breast and ovary cancer cases 2Health News:Women are better at forgiving 2Health News:Competing risks analysis highlights new targets in preventing ESRD and death of diabetics 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 3
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Medicine Products: